皮膚科用薬剤の世界市場:皮膚感染症薬、皮膚炎薬、にきび薬、乾癬薬

◆英語タイトル:Dermatological Drugs Market Forecast 2015-2025 : Opportunities for Leading Companies
◆商品コード:VGAIN5052605
◆発行会社(調査会社):visiongain
◆発行日:2015年5月
◆ページ数:310
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥242,865見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥404,865見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥674,865見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、皮膚科用薬剤の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・皮膚科用薬剤の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・皮膚科用薬剤の世界市場:セグメント別市場分析
 - 皮膚感染症治療薬市場
 - 皮膚炎治療薬市場
 - にきび治療薬市場
 - 乾癬治療薬市場
・地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Dermatological drugs – new study showing you trends, partnerships, and predicted revenues
Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain’s new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 310 page report provides 220 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
• Kathleen Deardorff, Chief Operating Officer (COO) at Photocure ASA

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
• Skin infection drugs market forecast 2015-2025
• Dermatitis drugs market forecast 2015-2025
• Acne drugs market forecast 2015-2025
• Psoriasis drugs market forecast 2015-2025
• Other dermatological drugs market forecast 2015-2025

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 24 products, including these brands:
• Remicade
• Humira
• Claravis
• Epiduo
• Bepanthen
• Solodyn
• Enbrel
• Protopic
• Cubicin
• Canesten


Discover how high revenues can go. You will see what’s happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
Our analyses show sustained growth in the dermatological drugs market, particularly in the emerging economies where growing affluence and rising government support will impact the growth of dermatological drugs.

In addition to analyses of the overall world market, you discover individual revenue forecasts for national and regional markets to 2025. Future trends within each region are examined. You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
• US
• China
• Japan
• Germany
• India
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• Mexico
• Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth
Over the last few years, the market for dermatological drugs globally has witnessed a number of strategic acquisitions and restructuring. The global dermatological drugs market will reach $24.5bn in 2015, according to visiongain’s forecast. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs, and antibacterial drug resistance will aid in the growth of the overall market to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
• AbbVie
• Galderma
• GlaxoSmithKline
• Johnson & Johnson
• LEO Pharma
• Pfizer

【レポートの目次】

1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction To Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction To Dermatology
2.2.1 The Structural Lay-out Of The Skin, Hair, And Nails
2.2.2 Hair And Nails
2.2.3 Sweat And Sebaceous Glands
2.2.4 Functions Of The Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes And Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation Of The Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding Of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases Of Clinical Trials
2.12 Dermatological Drugs: Market Definition In This Report

3. The Global Dermatological Drugs Market, 2015-2025
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation Of The Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market In 2014
3.4 The Global Dermatological Drugs Market: Market Forecast 2015-2025
3.5 Dermatological Drugs: Changing Market Shares By Sector 2015-2025

4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Psoriasis Treatments: The Dominance Of Biologics
4.1.1 Leading Products In The Psoriasis Drugs Market, 2014
4.2 Psoriasis: Market Trends And Developments, 2015
4.2.1 Biological Drugs In Psoriasis Treatment: A Brief Overview
4.2.2 Issues Around Patent Protection, The Threat Of Biosimilars And Pricing
4.2.3 The Disadvantages Of Biologics In Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2015-2025
4.3.1 Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs Used In The Treatment Of Psoriasis
4.5 Humira (adalimumab) – AbbVie
4.5.1 Humira: Historical Sales Analysis, 2010-2014
4.5.2 Humira: Sales Forecast 2015-2025
4.5.3 Future Prospects For Biosimilar Versions Of Humira
4.6 Stelara (ustekinumab) – Johnson & Johnson
4.6.1 Stelara: Historical Sales Analysis, 2010-2014
4.6.2 Stelara: Sales Forecast 2015-2025
4.6.3 Intensifying Competition For Stelara
4.7 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.7.1 Enbrel: Co-Promotions And Marketing Rights
4.7.2 Enbrel: Historical Sales Analysis, 2008-2014
4.7.3 Enbrel: Patent Expiries and Potential Competition, 2015-2025
4.7.4 Enbrel: Sales Forecast 2015-2025
4.7.5 Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years
4.7.6 Competition From Other Drugs
4.7.7 Biosimilar Competition For Enbrel
4.8 Remicade (infliximab) – Johnson & Johnson
4.8.1 Remicade: Historical Sales Analysis, 2010-2014
4.8.2 Remicade: Patent Expiries and Potential Competition, 2015-2025
4.8.3 Remicade: Sales Forecast 2015-2025
4.9 Daivobet (betamethasone/calcipotriene) – LEO Pharma
4.9.1 Daivobet: Sales Forecast 2015-2025
4.9.2 LEO Pharma’s Life Cycle Management Of Daivobet
4.9.3 Daivobet/Dovobet/Taclonex – Generic Competition
4.10 Soriatane (acitretin) – GlaxoSmithKline
4.10.1 Soriatane: Sales Forecast 2015-2025
4.11 Other Psoriasis Drugs
4.11.1 Cimzia (certolizumab) – UCB
4.11.2 Cosentyx (secukinumab) – Novartis
4.11.3 Otezla (apremilast) – Celgene
4.11.4 Sorilux (calcipotriene foam) – GSK
4.11.5 Other Psoriasis Drugs: Sales Forecast 2015-2025
4.12 Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products In The Skin Infection Drugs Market, 2014
5.2 Skin Infection Drugs: Market Forecast 2015-2025
5.2.1 Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs Used In The Treatment Of Skin Infections
5.4 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.4.1 Acquisition By Merck & Co
5.4.2 Generic Competition For Cubicin
5.4.3 Cubicin: Sales Forecast 2015-2025
5.4.4 Lifecycle Management Strategies For Cubicin
5.5 Zyvox (linezolid) – Pfizer
5.5.1 Zyvox: Historical Sales Analysis, 2010-2014
5.5.2 Zyvox: Sales Forecast 2015-2025
5.5.3 The Threats To Zyvox Sales From Competing New Drugs
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2015-2025
5.7 Canesten (clotrimazole) – Bayer
5.7.1 Canesten: Historical Sales Analysis, 2011-2014
5.7.2 Canesten: Sales Forecast 2015-2025
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2015-2025
5.9 Bactroban (mupirocin) – GSK
5.9.1 Bactroban: Historical Sales Analysis, 2010-2013
5.9.2 Bactroban: Sales Forecast 2015-2025
5.10 Other Skin Infection Drugs
5.10.1 Dalvance (dalbavancin) – Durata Therapeutics
5.10.2 Jublia (efinaconazole) – Valeant
5.10.3 Kerydin (tavaborole) – Anacor
5.10.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.10.5 Zovirax (acyclovir) – Valeant/GSK
5.10.5.1 Valeant Acquires Zovirax In US And Canada
5.10.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.10.6 Other Skin Infection Drugs: Sales Forecast 2015-2025
5.11 Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products In The Acne Drugs Market, 2014
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise Of Combination Therapies In Acne Treatment
6.2.2 Oral Contraceptives In Treating Acne
6.2.3 The Threat Of Generic Competition In The Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2025
6.3.1 Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs In The Acne Drugs Market
6.5 Solodyn (minocycline) – Valeant
6.5.1 Solodyn: Sales Forecast 2015-2025
6.5.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.5.3 Impax And Medicis Collaborating On Advanced Solodyn
6.5.4 Medicis And Lupin Settle
6.6 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.6.1 Epiduo: Sales Forecast 2015-2025
6.6.2 Galderma Settlement Agreement Over Generic Epiduo
6.6.3 Paediatric Approval For Epiduo
6.7 Claravis (isotretinoin) – Teva
6.7.1 Claravis: Sales Forecast 2015-2025
6.8 Aczone (dapsone) – Allergan
6.8.1 Aczone: Sales Forecast 2015-2025
6.9 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.9.1 Recent Generic Competition To Differin
6.9.2 Differin: Sales Forecast 2015-2025
6.9.3 Federal Circuit Court Invalidates Differin Patents
6.10 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.10.1 Absorica/Epuris: Sales Forecast 2015-2025
6.11 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.11.1 Valeant’s Patent Settlement With Actavis Over Ziana
6.11.2 Ziana: Sales Forecast 2015-2025
6.12 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.12.1 Lifecycle Management Strategies For Doryx
6.12.2 Divestment Agreement With Mayne Pharma
6.12.3 Generic Competition For Doryx
6.12.4 Doryx: Sales Forecast 2015-2025
6.13 Other Acne Drugs
6.13.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.13.1.1 Acanya: Financial Analysis
6.13.1.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.13.1.3 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.13.2 Amnesteem (isotretinoin) – Mylan
6.13.2.1 Amnesteem: Financial Analysis
6.13.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.13.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.13.4.1 Duac: Financial Analysis
6.13.5 Veltin (tretinoin/clindamycin) – GSK
6.13.6 Other Acne Drugs: Sales Forecast 2015-2025
6.14 Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products In The Dermatitis Drugs Market, 2014
7.2 Dermatitis Drugs: Market Forecast 2015-2025
7.2.1 Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.3 Leading Drugs In The Dermatitis Drugs Market
7.4 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.4.1 Bepanthen: Sales Forecast 2015-2025
7.5 Protopic (tacrolimus) – Astellas Pharma/ Roche
7.5.1 Protopic Benefits From Expanded Indication
7.5.2 Generic Competition For Protopic
7.5.3 Protopic: Sales Forecast 2015-2025
7.6 Elidel (pimecrolimus) – Meda Pharma/ Valeant
7.6.1 Elidel: Sales Forecast 2015-2025
7.7 Elocon (mometasone) – Merck & Co
7.7.1 Elocon: Sales Forecast 2015-2025
7.8 Other Dermatitis Drugs: Sales Forecast 2015-2025
7.9 Dermatitis Drugs: Market Outlook

8. Leading National Markets For Dermatological Drugs, 2015-2025
8.1 The Dermatological Drugs Market By Region
8.1.1 The Global Distribution Of Dermatological Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Dermatological Drugs Market
8.4.1 The Impact Of An Expanding Medicare Coverage
8.4.2 Legislative Environment Stimulating Biosimilars Market?
8.4.3 US Dermatological Drugs Market: Market Forecast 2015-2025
8.5 The EU5 Markets: Growth Expected In Each Country
8.5.1 EU5 Dermatological Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Dermatological Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Dermatological Drugs Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Dermatological Drugs Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Dermatological Drugs Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Dermatological Drugs Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Dermatological Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Improving Public Perception Of Dermatology In China
8.7.3 Price Controls And The Anhui Model
8.7.4 Chinese Dermatological Drugs Market Forecast 2015-2025
8.8 India
8.8.1 The Effects Of The Drug Prices Control Order Of 2013
8.8.2 India’s Expansion Of Healthcare Provision
8.8.3 Indian Dermatological Drugs Market Forecast 2015-2025
8.9 Brazil
8.9.1 The Growth In Brazil’s Healthcare Landscape
8.9.2 Clearer Access To Medicines In Brazil
8.9.3 Brazilian Dermatological Drugs Market Forecast 2015-2025
8.10 Russia
8.10.1 Pharma2020 Strategy – Healthcare And Industry Reform
8.10.2 Russian Dermatological Drugs Market Forecast 2015-2025
8.11 Mexico
8.11.1 Seguro Popular: Mexican Healthcare Reform
8.11.2 Are Multinationals Waking Up To Mexico’s Potential?
8.11.3 Mexican Dermatological Drugs Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 The Rest of the World Dermatological Drugs Market Forecast 2015-2025

9. Leading Companies In The Dermatological Drugs Market, 2015-2025
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2015
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition Of Galderma
9.2.2.2 Approval Of Soolantra For Rosacea
9.2.2.3 Mirvaso Launched For Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson Dermatological Drugs Sales Forecast 2015-2025
9.3.3 Johnson And Johnson: Dermatological Drug Development Efforts, 2015
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2015
9.4.2 AbbVie Dermatological Drugs Sales Forecast 2015-2025
9.4.3 AbbVie: Dermatological Drugs Development Pipeline, 2015
9.4.3.1 BT-061 (tregalizumab) For The Treatment Of Psoriasis
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2015
9.5.2 GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.3.2 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2015
9.6.2 Pfizer Dermatological Drugs Sales Forecast 2015-2025
9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2015
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2015
9.7.2 LEO Pharma Dermatological Drugs Sales Forecast 2015-2025

10. Dermatological Drugs: Research And Development Pipeline, 2015-2025
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 New Technology In R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms And Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2015
10.2.1 Psoriasis Drugs In Phase 3 Development
10.2.1.1 000-0551 Lotion (halobetasol) – Therapeutics, Inc
10.2.1.2 AMG 827 (brodalumab) – AstraZeneca/ Amgen
10.2.1.3 CF101 (IB-MECA) – Can-Fite BioPharma
10.2.1.4 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.5 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.6 LEO 90100 – LEO Pharma
10.2.1.7 LY2439821 (ixekizumab) – Eli Lilly
10.2.1.8 MK-3222/SCH 900222 (tildrakizumab) – Merck
10.2.1.9 STF 115469 (calcipotriene foam) – GSK
10.2.1.10 Xeljanz (tofacitinib) – Pfizer
10.2.2 Psoriasis Drugs In Phase 2 Development
10.2.2.1 AN2728 (PDE-4 inhibitor) – Anacor Pharmaceuticals
10.2.2.2 CT327 (TrkA inhibitor) – Creabilis Therapeutics
10.2.2.3 ASP015K (JAK inhibitor) – Astellas Pharma
10.2.2.4 Jakavi/Jakafi (ruxolitinib) – Incyte/ Novartis
10.2.2.5 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.6 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs In Phase 1 And Pre-clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Skin Infections
10.3.1.1 Delafloxacin (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Orbactiv/ Nuvocid (oritavancin) – The Medicines Company
10.3.1.4 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs In Phase 2 Development For Skin Infections
10.3.3 Drugs In Phase 1 And Preclinical Pipeline For Skin Infections
10.4 Acne Drugs Development Pipeline, 2015
10.4.1 Drugs In Phase 3 Development For Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs In Phase 2 Development For Acne
10.4.3 Drugs In Phase 1 And Pre-clinical Development For Acne
10.4.4 A Possible Vaccine For Acne
10.5 Dermatitis Drugs Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.1.5 Soriatane (acitretin) – InnovaDerm/Tribute Pharmaceuticals
10.5.2 Drugs In Phase 2 Development For Dermatitis
10.5.3 Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2015
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Keytruda (MK-3475, Pembrolizumab) – Merck
10.6.1.4 Mirvaso (brimonidine) – Galderma
10.6.1.5 Picato (ingenol mebutate) – LEO Pharma
10.6.1.6 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2015
10.6.2.1 Atralin (tretinoin) – Valeant
10.6.2.2 BMS-936558 (nivolumab) – Bristol-Myers Squibb
10.6.2.3 CD5024 (ivermectin) – Galderma
10.6.2.4 Latisse (bimatoprost) – Allergan (Actavis)
10.6.2.5 LEE011, LGX818, and MEK162 – Novartis
10.6.2.6 Oleogel-S10 (triterpene extract) – Birken AG
10.6.2.7 PV-10 (Rose Bengal) – Provectus Pharmaceuticals
10.6.2.8 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.2.9 TVEC (talimogene laherparepvec) – Amgen
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2015
10.6.4 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline

11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need In Dermatology
11.2.1.2 A Healthy Pipeline Of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy And Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge To Treatment Design
11.2.2.3 Impending Patent Expiries And The Challenges Posed By Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors In Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances In Genomics
11.2.3.3 Advances In Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation Within Dermatology – Opportunity For Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement And Payment Approvals
11.2.4.2 The Rising Cost Of Research And Development
11.2.4.3 Downward Pressures On Drug Prices
11.3 Porter’s Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.3.1 Threat Of New Entrants
11.3.2 Threat Of Substitutes
11.3.3 Rivalry Among Competitors
11.3.4 Power Of Buyers
11.3.5 Power Of Suppliers

12. Expert Opinions from Our Primary Research
12.1 Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA
12.1.1 Visonac As An Innovative First-In-Class Treatment
12.1.2 Photocure’s Development Plans For Visonac
12.1.3 Commercialisation Strategy For Visonac
12.1.4 On The Geographical Reach Of Acne Treatments
12.1.5 The Key Unmet Needs Within Patient Populations For Acne
12.1.6 The Key Forces Driving And Restraining The Development Of Acne Therapies
12.1.7 On The Current Development Pipeline For Acne Therapies
12.1.8 On Photocure’s Plans For Future Growth
12.1.9 Future Prospects For The Acne Treatments Market

13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Dermatological Drugs In 2014
13.3 Leading Regions In The Dermatological Drugs Market In 2014
13.4 Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025
13.5 What Does The Future Hold For Dermatological Drugs?

List of Tables
Table 1.1 Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025 (Redacted Data)
Table 2.1 Clinical Trial Phases, 2015
Table 3.1 The Global Dermatological Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
Table 3.2 The Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2014-2025
Table 3.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
Table 3.4 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
Table 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($m) and Market Shares (%), 2014
Table 4.2 Psoriasis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 4.3 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 4.4 Humira: Historical Sales ($m, AGR%), 2010-2014
Table 4.5 Humira: AbbVie Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.6 Stelara: Historical Sales ($m, AGR%), 2010-2014
Table 4.7 Stelara: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.8 Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2014
Table 4.9 Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.10 Remicade: Historical Sales ($m, bn Yen, AGR%), 2010-2014
Table 4.11 Remicade: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.12 Daivobet: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.13 Soriatane: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.14 Other Psoriasis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.1 Top Drugs In The Skin Infection Drugs Market: Revenue ($m) and Market Share (%), 2014
Table 5.2 Skin Infection Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 5.3 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 5.4 Cubicin: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.5 Zyvox: Historical Sales ($m, AGR%), 2010-2014
Table 5.6 Zyvox: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.7 Valtrex: Historical Sales ($m, £m, AGR%), 2010-2014
Table 5.8 Valtrex: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.9 Canesten: Historical Sales ($m, Euros, AGR%), 2011-2014
Table 5.10 Canesten: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.11 Lamisil: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.12 Bactroban: Historical Sales ($m, Euros, AGR%), 2010-2013
Table 5.13 Bactroban: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.14 Other Skin Infection Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.1 Top Drugs In The Acne Drugs Market: Revenue ($m) and Market Share (%), 2014
Table 6.2 Acne Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 6.3 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 6.4 Solodyn (Valeant): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.5 Epiduo (Galderma/ Nestlé): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.6 Claravis (Teva): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.7 Aczone (Allergan): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.8 Differin (Galderma/ Nestlé): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.9 Absorica/Epuris: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.10 Ziana: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.11 Doryx: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.12 Other Acne Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($m) and Market Share (%), 2014
Table 7.2 Dermatitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 7.3 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 7.4 Bepanthen/Bepanthol: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.5 Protopic: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.6 Elidel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.7 Elocon: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.8 Other Dermatitis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.1 The Global Dermatological Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
Table 8.2 Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
Table 8.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
Table 8.4 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.6 US Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.7 The EU5 Dermatological Drugs Market: Revenue ($m), and Market Share (%) by Country, 2014
Table 8.8 The EU5 Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.9 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.11 The German Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.13 The French Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.15 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.17 The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.19 The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.21 The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.23 The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.25 The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.27 The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.29 The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.30 The Mexican Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.31 The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.32 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
Table 8.33 The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.1 Galderma: Company Overview, 2013 And 2014
Table 9.2 Johnson & Johnson: Company Overview, 2014
Table 9.3 Johnson & Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.4 AbbVie: Company Overview, 2014
Table 9.5 AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.6 GlaxoSmithKline: Company Overview, 2014
Table 9.7 GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.8 GlaxoSmithKline: Dermatological Drugs Pipeline, 2015
Table 9.9 Pfizer: Company Overview, 2014
Table 9.10 Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.11 LEO Pharma: Company Overview, 2014
Table 9.12 LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2015
Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2015
Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.13 Other Dermatological Drugs Pipeline: Phase 1 and Preclinical Drugs, 2015
Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2015-2025
Table 13.1 Global Dermatological Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
Table 13.2 The Global Dermatological Drugs Market: Market Size ($m) and Market Shares (%) by Sector, 2014
Table 13.3 The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025
Table 13.4 The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025

List of Figures
Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2015
Figure 1.2 Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Altered Data)
Figure 2.1 Anatomy of the Human Skin
Figure 3.1 The Global Dermatological Drugs Market: Revenue ($m) by Sector, 2014
Figure 3.2 The Global Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 3.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019
Figure 3.4 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2019-2025
Figure 3.5 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2025
Figure 3.6 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014
Figure 3.7 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2019
Figure 3.8 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2025
Figure 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($m), 2014
Figure 4.2 Psoriasis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 4.3 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 4.4 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 4.5 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 4.6 Humira: Historical Sales ($m, AGR%), 2010-2014
Figure 4.7 Humira: AbbVie Sales Forecast ($m, AGR%), 2014-2025
Figure 4.8 Stelara: Historical Sales ($m, AGR%), 2010-2014
Figure 4.9 Stelara: Sales Forecast ($m, AGR%), 2014-2025
Figure 4.10 Enbrel: Historical Sales ($m) by Company, 2008-2014
Figure 4.11 Enbrel: Sales Forecast ($m, AGR%), 2014-2025
Figure 4.12 Remicade: Historical Sales ($m, AGR%), 2010-2014
Figure 4.13 Remicade: Sales Forecast ($m, AGR%), 2014-2025
Figure 4.14 Daivobet: Sales Forecast ($m, AGR%), 2014-2025
Figure 4.15 Soriatane: Sales Forecast ($m, AGR%), 2014-2025
Figure 4.16 Other Psoriasis Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.1 Top Drugs In The Skin Infection Drugs Market: Revenue ($m), 2014
Figure 5.2 Skin Infection Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 5.3 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 5.4 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 5.5 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 5.6 Cubicin: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.7 Zyvox: Historical Sales ($m, AGR%), 2010-2014
Figure 5.8 Zyvox: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.9 Valtrex: Historical Sales ($m, AGR%), 2010-2014
Figure 5.10 Valtrex: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.11 Canesten: Historical Sales ($m, AGR%), 2011-2014
Figure 5.12 Canesten: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.13 Lamisil: Novartis Sales Forecast ($m, AGR%), 2014-2025
Figure 5.14 Bactroban: Historical Sales ($m, AGR%), 2010-2013
Figure 5.15 Bactroban: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.16 Other Skin Infection Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.1 Top Drugs In The Acne Drugs Market: Revenue ($m), 2014
Figure 6.2 Acne Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 6.3 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 6.4 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 6.5 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 6.6 Solodyn (Valeant): Sales Forecast ($m, AGR%), 2014-2025
Figure 6.7 Epiduo (Galderma/ Nestlé): Sales Forecast ($m, AGR%), 2014-2025
Figure 6.8 Claravis (Teva): Sales Forecast ($m, AGR%), 2014-2025
Figure 6.9 Aczone (Allergan): Sales Forecast ($m, AGR%), 2014-2025
Figure 6.10 Differin (Galderma/ Nestlé): Sales Forecast ($m, AGR%), 2014-2025
Figure 6.11 Absorica/Epuris: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.12 Ziana: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.13 Doryx: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.14 Other Acne Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($m), 2014
Figure 7.2 Dermatitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 7.3 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 7.4 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 7.5 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 7.6 Bepanthen/Bepanthol: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.7 Protopic: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.8 Elidel: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.9 Elocon: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.10 Other Dermatitis Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 8.1 The Global Dermatological Drugs Market: Market Size ($m) by Region, 2014
Figure 8.2 US, EU5, and Japan Dermatological Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.3 Brazil, Russia, India, China, and Mexico Dermatological Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.4 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2019
Figure 8.5 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2019-2025
Figure 8.6 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2025
Figure 8.7 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2014
Figure 8.8 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2019
Figure 8.9 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2025
Figure 8.10 US Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.11 The EU5 Dermatological Drugs Market: Revenue ($m) by Country, 2014
Figure 8.12 Germany, France, UK, Italy, and Spain Dermatological Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.13 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2014
Figure 8.14 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2019
Figure 8.15 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2025
Figure 8.16 The German Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.17 The French Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.18 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.19 The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.20 The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.21 The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.22 The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.23 The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.24 The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.25 The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.26 The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.27 The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 9.1 Johnson & Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.2 AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.3 GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.4 Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.5 LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 11.1 Porter’s Five Force Analysis of the Dermatological Drugs Market, 2015
Figure 13.1 Global Dermatological Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025
Figure 13.2 The Global Dermatological Drugs Market: Market Size ($m) by Sector, 2014
Figure 13.3 The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014-2025
Figure 13.4 The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025

【掲載企業】

Abbott Laboratories
AbbVie
AbGenomics
Actavis
Actelion
AET BioTech
Affinium (DebioPharm Group)
AiCuris
Alembic Pharmaceuticals
Alkem Laboratories
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
AndroScience Group
AnGes M G
Anterios
Apeiron Biologics
Ascend Therapeutics
Astellas Pharma
Astion Pharma
AstraZeneca
Asubio Pharma (Daiichi Sankyo)
Atrix Laboratories
Aurobindo Pharma
Ausio Pharmaceuticals
Barr Laboratories
Basilea Pharmaceutica
Bayer
Boehringer Ingelheim
Berg Pharma
Bertek Pharmaceuticals
Biocon
Biofrontera
Biogen Idec
Biotest AG
Biovail Laboratories
BioXpress Therapeutics
Birken AG
Braintree Laboratories
Bristol-Myers Squibb
Cadila Healthcare
Can-Fite Biopharma
Cardinal Health
Celgene
Cellceutix
Celltech
Celltrion
Celsus Therapeutics
Cempra
Cipher Pharmaceuticals
Cipla
Circassia
CollaGenex
Compañía Internacional de Comercio
Convoy Therapeutics
Cosmo Pharmaceuticals
Creabilis Therapeutics
Cubist Pharmaceuticals
Cutanea Life Sciences
DAVA Pharmaceuticals
Delenex Therapeutics
Dermira Inc
Dow Pharmaceutical Sciences
Dr Reddy’s Laboratories
Durata Therapeutics
Eisai
Eli Lilly
Elorac
Foamix
Fortuderm
Forward Pharma
Fougera Pharmaceuticals (Sandoz)
Fujifilm
Fujisawa Healthcare
Furiex Pharmaceuticals
G&E Herbal Biotechnology
G&W Laboratories
Galderma (Nestle)
Gene Signal
Genentech (Roche)
Genpharm
Genzyme (Sanofi)
GlaxoSmithKline
Glenmark Pharmaceuticals
Grupo Imperial
Hanwha Pharma
Heritage Pharmaceuticals
Hospira
Idera Pharmaceuticals
Immune Response BioPharma Inc
Immunex
Impax Laboratories
Incyte
Innovaderm Research
Instituto Terapeutico Delta Ltda
Intrepid Therapeutics
Janssen Biotech
Johnson & Johnson
Kosei
Kyowa Hakko Kirin
L’Oreal
Laboratorios Kendrick
LEO Foundation
LEO Pharma
Lupin Pharmaceuticals
Maruho
Meda Pharma
Medicis (Valeant)
Medison Pharma
Melinta Pharmaceuticals
Merck & Co
Mitsubishi Tanabe Pharma
Moleculin
MorphoSys
Mycenax Biotech
Mylan
Nabriva Therapeutics
NanoBio Corporation
Nestle
NovaBay
Novartis
OpthaliX
Par Pharmaceutical
Paratek Pharmaceuticals
Peplin (LEO Pharma)
Perrigo
Pfizer
Pharmacia (Pfizer)
PharmaPraxis
Photocure
Pierre Fabre
Pliva Hrvatska
Precision Dermatology
Provectus Biopharmaceuticals
Q-Med
Ranbaxy
Regeneron
Roche
Rochester Drug Co-operative
Roxane Laboratories
S.A.P.I. de C.V. (CISCA)
Samsung Bioepis
Sandoz (Novartis)
Sanofi
Shape Pharmaceuticals
Shionogi & Co
Sidmak Laboratories
Sol-Gel Technologies
Stiefel Laboratories (GSK)
Sun Pharmaceuticals
Sunovion Pharmaceuticals
Switch Biotech
Taisho Pharmaceuticals
Takeda
Targanta Therapeutics
Taro Pharmaceuticals
Tecnofarma
Telormedix
Teva
The Medicines Company
Therapeutics Inc
Theravance
Tolmar Inc
Topica Pharmaceuticals
Trius Therapeutics
UCB Pharma
Valeant Pharmaceuticals
Vatera Healthcare Partners
VBL Therapeutics
Vedara Therapeutics
ViiV Healthcare (GSK)
ViroBay
Vitacilina Corporation of America (VitaCorp)
Warner Chilcott (Actavis)
Welichem Biotech
Wolters Kluwer
Wyeth (Pfizer)
XBiotech
XenoPort
Xoma

【レポートのキーワード】

皮膚科用薬剤、皮膚感染症治療薬、皮膚炎治療薬、にきび治療薬、乾癬治療薬、皮膚病治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[皮膚科用薬剤の世界市場:皮膚感染症薬、皮膚炎薬、にきび薬、乾癬薬]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年08月30日現在 204,134 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆